On Wednesday, Goldman Sachs reiterated a Neutral rating with a steady $41.00 price target on shares of Tarsus Pharmaceuticals (NASDAQ:TARS), currently trading at $44.33 with a market capitalization of $1.69 billion. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $41 to $84.

The firm’s stance comes as Tarsus discussed its 2025 outlook, highlighting growth opportunities, particularly regarding the development of TP-04, a topical gel for treating ocular rosacea. Ocular rosacea is believed to be caused by Demodex mite infestation, and there is evident interest and demand from eye care practitioners for such a product.

Tarsus is currently finalizing the assessments and scales to…